EVALUATION IN YOUNG CHILDREN OF THE URABE AM 9 STRAIN OF LIVE ATTENUATED MUMPS VACCINE IN COMPARISON WITH THE JERYL LYNN STRAIN
- 21 January 1983
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 72 (1), 37-40
- https://doi.org/10.1111/j.1651-2227.1983.tb09660.x
Abstract
Urabe Am 9, a new strain of mumps vaccine, originally developed in Japan, was evaluated in children 14 to 20 months of age in a comparative trial with the Jeryl Lynn strain. Both vaccines performed well. The antibody responses were measured using a neutralization test and a haemolysis-in-gel test. The seroconversion rates at six weeks, as detected with either one or both tests, were 55/58 (94.8%) after the Urabe Am 9 and 58/60 (96.7%) after the Jeryl Lynn vaccine. Only mild infrequent adverse reactions were observed. It is concluded that both strains of live attenuated mumps vaccine are immunogenic and well-tolerated in this age group.Keywords
This publication has 6 references indexed in Scilit:
- COMPARISON OF THE URABE AM 9‐SCHWARZ AND JERYL LYNN‐MORATEN COMBINATIONS OF MUMPS‐MEASLES VACCINES IN YOUNG CHILDRENActa Paediatrica, 1983
- Prevention of mumps.BMJ, 1980
- Current Status of Mumps and Mumps Vaccine in the United StatesPEDIATRICS, 1978
- Determination of mumps and influenza antibodies by haemolysis-in-gelArchiv für die gesamte Virusforschung, 1976
- Live, Attenuated Mumps-Virus VaccineNew England Journal of Medicine, 1968
- Live, Attenuated Mumps-Virus VaccineNew England Journal of Medicine, 1967